Impact of B.1.617 and RBD SARS-CoV-2 variants on vaccine efficacy: An in-silico approach
Open Access
- 1 April 2022
- journal article
- research article
- Published by Elsevier in Indian Journal of Medical Microbiology
- Vol. 40 (3) , 413-419
Abstract
No abstract availableKeywords
All Related Versions
Funding Information
- Banaras Hindu University
This publication has 24 references indexed in Scilit:
- Potential for developing a SARS-CoV receptor-binding domain (RBD) recombinant protein as a heterologous human vaccine against coronavirus infectious disease (COVID)-19Human Vaccines & Immunotherapeutics, 2020
- Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2Science, 2020
- Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS CoronavirusJournal of Virology, 2020
- An in silico analysis of deleterious single nucleotide polymorphisms and molecular dynamics simulation of disease linked mutations in genes responsible for neurodegenerative disorderJournal of Biomolecular Structure and Dynamics, 2019
- The RosettaDock server for local protein-protein dockingNucleic Acids Research, 2008
- GROMACS 4: Algorithms for Highly Efficient, Load-Balanced, and Scalable Molecular SimulationJournal of Chemical Theory and Computation, 2008
- Structural Basis of Neutralization by a Human Anti-severe Acute Respiratory Syndrome Spike Protein Antibody, 80RJournal of Biological Chemistry, 2006
- UCSF Chimera—A visualization system for exploratory research and analysisJournal of Computational Chemistry, 2004
- Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor associationProceedings of the National Academy of Sciences, 2004
- LIGPLOT: a program to generate schematic diagrams of protein-ligand interactionsProtein Engineering, Design and Selection, 1995